Puma Q2 adjusted EPS beats expectations
Overview
Puma Q2 2025 product revenue rises to $49.2 mln, driven by NERLYNX demand
Adjusted EPS for Q2 beats analyst expectations, per LSEG data
Co reports net income of $5.9 mln for Q2, reversing prior year loss
Outlook
Puma expects Q3 net product revenue between $46 mln and $48 mln
Company forecasts full-year total revenue of $212–$222 mln
Puma anticipates Q3 net income between $2 mln and $4 mln
Company sees full-year net income of $23–$28 mln
Result Drivers
NERLYNX SALES - Increased demand for NERLYNX drove product revenue to $49.2 mln in Q2 2025
EXPENSE REDUCTION - Lower SG&A expenses due to decreased legal fees contributed to profitability
ALISERTIB DEVELOPMENT - Increased R&D expenses linked to alisertib study activity
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Revenue |
| $49.20 mln |
|
Q2 Adjusted EPS | Beat | $0.15 | $0.1 (3 Analysts) |
Q2 EPS |
| $0.12 |
|
Q2 Adjusted Net Income | Beat | $7.50 mln | $4.20 mln (2 Analysts) |
Q2 Net Income |
| $5.90 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Puma Biotechnology Inc is $4.00, about 18.8% above its August 6 closing price of $3.25
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago
Press Release: ID:nBw8yfNtda
